Novo Nordisk H1 2026 Earnings: DKK 175.3B Sales, DKK 69.5B Net Profit, Outlook 'Raised' to 0% to −6%
Novo Nordisk's H1 2026 results — DKK 175.3B net sales, DKK 69.5B net profit, Q2 adjusted operating profit up 11% at CER — against full-year guidance of 0% to −6% adjusted growth. A double-entry Beancount breakdown of the 340B rebate bridge, DKK 6.3B impairments, and the GLP-1 franchise's shift from scarcity to pricing pressure.